Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
09.03.2016
Veloxis Pharmaceuticals A/S moves Danish activates to the U.S.
Veloxis Pharmaceuticals A/S ("Veloxis") has decided to close its office in Hørsholm, Denmark, and move all activities to the U.S. where most of the company's current activities is already located. The process is expected to be completed during the second half of 2016.
Dato
07.03.2016
Vtesse, Inc. Announces Phase 1/2 Clinical Data Showing Slowing of Disease Progression from VTS-270 Treatment for Niemann-Pick Type C1 Disease
GAITHERSBURG, Md., March 4, 2016 /PRNewswire/ -- Vtesse, Inc. announced today data from a Phase 1/2 clinical trial demonstrating a reduction in the rate of Niemann-Pick Type C1 (NPC1) Disease progression from Vtesse's lead drug candidate VTS-270. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Center for Advancing Translational Sciences, two components of the National Institutes of Health, collaborated closely with patients, patient advocacy groups and academia to initiate the drug development phase for VTS-270. Vtesse is leading the late-stage formal drug development process.
Dato
03.03.2016
scPharmaceuticals Announces Positive Results from Pivotal Trial of Second Program – Subcutaneous Ceftriaxone for Treatment of Bacterial Infections
Antibacterial coverage (time over MIC) equivalent to coverage following standard intravenous administration.
Novel route of administration is free from common and serious risks associated with intravenous infusion lines and deep intramuscular injections.


LEXINGTON, Mass., March 2, 2016 /PRNewswire/ -- scPharmaceuticals, Inc., announced today that the pivotal trial for its ceftriaxone program met the targeted end-points. The primary end-point for the study is non-inferior antimicrobial coverage when compared to the same dose given by intravenous infusion. Antimicrobial coverage refers to time over the Minimum Inhibitory Concentration (MIC), a generally accepted measure of the adequacy of plasma levels of an antibiotic for treatment of infections due to susceptible bacteria.

Dato
02.03.2016
Ziarco Pharma Ltd: Appointment of Dr. Arvind Hundal as Chief Business Officer
DISCOVERY PARK, SANDWICH, England--(BUSINESS WIRE)--Ziarco Pharma Ltd. (“Ziarco” or “the Company”), a biopharmaceutical company focusing on the development of novel drugs for the treatment of inflammatory skin disorders, today announced the appointment of Dr Arvind Hundal as its Chief Business Officer (CBO), effective immediately.
Dato
02.03.2016
DySIS Medical Signs Significant Deal with ITEM Medical Technologies to Support National Screening Programme in Turkey

DySIS Colposcope to be incorporated into national cervical screening programme

EDINBURGH, Scotland--(BUSINESS WIRE)--DySIS Medical Ltd. (DySIS) today announces that it has signed a multi-million pound contract with medical technology distributor, ITEM Medical Technologies as part of the national cervical screening programme in Turkey. No financial details have been disclosed.

Dato
02.03.2016
BONESUPPORT™ ANNOUNCES AVAILABILITY IN EUROPE OF CERAMENT™|G IN 5 mL VOLUME TO ADDRESS GROWING MARKET DEMAND

CERAMENT™|G 5 mL to be utilized for infection management and prophylaxis in diabetic foot procedures and small extremities


Lund, Sweden, (PRNEWSWIRE) March 1, 2016 – BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced an extension to the CERAMENT™|G product portfolio, adding a 5 mL volume to further develop the management of osteomyelitis (OM) and infection prophylaxis in diabetic foot and small extremities. CERAMENT™|G, which releases Gentamicin, received CE-mark in 2013, and is the first injectable antibiotic eluting bone substitute indicated to promote and protect bone healing in the management of bone infection. CERAMENT™|G is now available in 5 mL and 10 mL in CE-mark countries.

Dato
02.03.2016
Veloxis appoints Alastair McEwan as new Chief Operating Officer
Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Alastair McEwan has been appointed as Chief Operating Officer.
Dato
02.03.2016
Cydan Development Celebrates Rare Disease Day with Gift to Support the NORD Natural History Project
Cambridge, Mass., February 29, 2016 – Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that impact the lives of people living with rare genetic diseases, today marked its support of Rare Disease Day with a gift to the National Organization of Rare Disorders (NORD) to support its Natural History Study Project being developed in collaboration with the U.S. Food and Drug Administration. 
Dato
05.02.2016
Phase 2a Psoriasis Study Initiated with Ziarco’s Lead Compound ZPL-389
Discovery Park, Sandwich, UK, - Ziarco Pharma Ltd., a biopharmaceutical company focusing on the development of novel drugs against inflammatory skin disorders, today announced that dosing has started in a Phase 2a proof of concept study in moderate to severe psoriasis with ZPL-389.  The Ziarco study commenced on schedule with results expected in H1 2017.
Dato
05.02.2016
BONESUPPORT™ REPORTS EXPANSION OF COMPANY’S CERAMENT™ DRUG ELUTING PROCEDURE REGISTRY
CERAMENTTM|G registry now includes 230 cases conducted in 18 hospitals across 9 countries - Registry now updated to include CERAMENTTM V procedures
Lund, Sweden, (PRNEWSWIRE) February 2, 2016 – BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today provided an update on the Company’s CERAMENT™ procedure registry, established by BONESUPPORT™ in February 2014 as part of the proactive postmarket surveillance process for the Company’s novel antibiotic eluting injectable bone substitutes. The CERAMENTTM|G registry now includes 230 cases conducted in 18 hospitals across 9 countries. In addition, the registry has recently been updated to include CERAMENTTM V procedures.


Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste